Articles tagged with 'Study' | BIOTRONIK

BIOTRONIK - Archive (Study)

2022
17
May
2022
| 09:32 Europe/Amsterdam
Two posters presented at the EuroPCR provided new insights into the safety profile of BIOTRONIK's Magmaris® Resorbable Magnesium Scaffold (RMS). BIOSOLVE-IV study investigator Prof. Dr. Jan Torzewski, Cardiovascular Center Oberallgäu-Kempten, Germany...
Read more
28
April
2022
| 08:13 Europe/Amsterdam
New long-term data presented at Charing Cross demonstrated the safety of BIOTRONIK’s Passeo®-18 Lux® paclitaxel drug-coated balloon (DCB) for the treatment of peripheral artery disease (PAD) in infrainguinal arteries. The independent analysis was led...
Read more
05
April
2022
| 07:18 Europe/Amsterdam
Final results from the BIO|GUARD-MI study show a 31 percent reduction of MACE in a sub-group analysis of patients with non-ST segment elevation myocardial infarction (NSTEMI). In the primary endpoint analysis of the total patient population, a trend ...
Read more
01
March
2022
| 09:27 Europe/Amsterdam
BIOTRONIK today announced final enrollment in the BIOMAG-I clinical trial1 by Prof. Michael Haude, Germany, the study’s coordinating clinical investigator and the principal investigator Prof. Javier Escaned, Spain. The prospective single-arm study as...
Read more
28
February
2022
| 14:27 Europe/Amsterdam
BIOTRONIK today announced five-year data from the BIOFLOW-V trial, which was presented yesterday at the 2022 CRT Conference during a late-breaking-clinical-trial session by Dr. David Kandzari, US Principal Investigator, Piedmont Heart Institute, Atla...
Read more
2021
08
November
2021
| 09:09 Europe/Amsterdam
Superiority of the Magmaris® sirolimus-eluting bioresorbable magnesium scaffold with regard to probable or definite scaffold thrombosis compared to a historical control group of Absorb scaffold data was demonstrated for the first time in a prospectiv...
Read more
27
September
2021
| 11:03 Europe/Amsterdam
 BIOTRONIK is proud to announce the enrollment of the first patient in the BIONETIC-I study of the safety and efficacy of the Dynetic®-35 cobalt chromium balloon-expandable stent system for the treatment of atherosclerotic peripheral artery disease l...
Read more
23
September
2021
| 08:53 Europe/Amsterdam
BIOTRONIK is proud to announce the completion of enrollment of the investigator-initiated BIOPACT randomized controlled trial (RCT). This non-inferiority study evaluates the safety and efficacy of paclitaxel drug-coated balloons (DCBs), comparing the...
Read more
20
August
2021
| 11:58 Europe/Amsterdam
BIOTRONIK has today announced an important online symposium hosting the principal investigator of the TRUST Trial1, the latest study calling for a reform to the current clinical standards for in-person patient evaluations (IPE), as part of this year’...
Read more
20
May
2021
| 13:33 Europe/Amsterdam
More than 200 years after James Lind experimented with citrus fruits as a way to fight scurvy in sailors – in what is thought to be the world’s first clinical trial – we mark May 20 as Clinical Trials Day. On this day, we spotlight and celebrate adva...
Read more
18
May
2021
| 09:00 Europe/Amsterdam
New, long-term follow-up data from the BIOSOLVE-IV real-world registry strengthens the clinical evidence for BIOTRONIK’s Magmaris® Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery disease. Prof. Jan Torzewski,...
Read more
2020
15
November
2020
| 17:56 Europe/Amsterdam
In their short time on the market, bioresorbable vascular scaffolds have generated plenty of discussion within interventional cardiology. According to the authors of “Fading Away or Hope for the Future,” published by the American College of Cardiolog...
Read more
29
October
2020
| 18:07 Europe/Amsterdam
About one in four people globally will have a stroke in their lifetimes. Stroke is the fifth-leading cause of death in the US and accounts for over a million deaths in Europe every year. The most common heart rhythm disorder—atrial fibrillation (AF)—...
Read more
24
August
2020
| 13:06 Europe/Amsterdam
Almost 30 years after the US FDA rescinded a ban on women of “childbearing potential” from participating in clinical studies, women remain underrepresented in many key areas for medical trials—including cardiovascular medicine. This is despite guidan...
Read more
13
May
2020
| 13:30 Europe/Amsterdam
Results just published in Circulation Arrhythmia and Electrophysiology confirm that BIOTRONIK Home Monitoring® provides safe and cost-effective remote management of pacemaker patients,1 indicating that it can safely replace the common practice of rou...
Read more
06
May
2020
| 09:24 Europe/Amsterdam
According to recently presented TICO trial data, patients with acute coronary syndrome (ACS) treated with BIOTRONIK’s Orsiro® drug eluting stent (DES) benefit from stopping aspirin three months after stenting and continuing only with ticagrelor monot...
Read more
24
February
2020
| 00:00 Europe/Amsterdam
BIOTRONIK today announced three-year data from the BIOFLOW-V trial, which was presented yesterday at the 2020 CRT Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinfo...
Read more
2019
18
October
2019
| 14:54 Europe/Amsterdam
About 30 percent of patients undergoing primary percutaneous coronary intervention (PCI) suffer from ST-Elevation Myocardial Infarction (STEMI) – the most acute form of coronary artery disease. It’s caused by a complete thrombotic occlusion and is as...
Read more
30
September
2019
| 00:00 Europe/Amsterdam
Full cohort data from the BIOSOLVE-IV registry strengthen the clinical evidence for BIOTRONIK’s Magmaris®1 Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery disease. Dr. Stefan Verheye, Senior Interventional Ca...
Read more
11
September
2019
| 00:00 Europe/Amsterdam
Twelve-month results of the BIOFLEX COF trial have demonstrated that the implantation of stents with low chronic outward force1 (COF) was associated with less neointimal hyperplasia2, consequently resulting in less restenosis. Patients treated with B...
Read more
22
July
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the publication of the SENSE Trial results in the Journal of Cardiac Electrophysiology, proving BIOTRONIK’s DX system is equivalent to dual-chamber implantable cardioverter defibrillators (ICDs) in detecting atrial high-rate...
Read more
07
June
2019
| 00:00 Europe/Amsterdam
New data from the BIOSOLVE-IV registry strengthen the clinical evidence for the Magmaris®1 resorbable scaffold device and procedure success and safety profile at one year. Dr. Stefan Verheye, Senior Interventional Cardiologist at Antwerp Cardiovascul...
Read more
27
May
2019
| 00:00 Europe/Amsterdam
BIOTRONIK announced today that the first patient for the BIO|MASTER.Cor Family study was enrolled at Pauls Stradins Clinical University Hospital in Riga, Latvia at the cardiology department led by Prof. Andrejs Erglis. The patient received a Rivacor ...
Read more
06
May
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced initial enrollment into the BIO-LIBRA study, a first-of-its kind, large-scale prospective study to analyze sex-specific outcomes in patients with non-ischemic cardiomyopathy (NICM) treated with cardiac defibrillator device t...
Read more
06
May
2019
| 00:00 Europe/Amsterdam
The observational THORN registry1 highlights the importance of rapid corrective action by medical staff in cases of inappropriate diagnosis and therapy using implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibri...
Read more
06
March
2019
| 00:00 Europe/Amsterdam
Three-year outcome data from the BIO-RESORT1 randomized controlled trial were presented in a late-breaking clinical trials session by Dr. Clemens von Birgelen, Thoraxcentrum Twente, MST, Enschede, The Netherlands. Results from this large three-arm tr...
Read more
05
March
2019
| 00:00 Europe/Amsterdam
Preliminary data from the BIOSOLVE-IV registry strengthen the clinical evidence in favor of BIOTRONIK’s resorbable magnesium scaffold Magmaris®1 for de novo coronary artery lesions. Presented as late-breaking clinical data at the Cardiovascular Resea...
Read more
04
March
2019
| 00:00 Europe/Amsterdam
Two-year data from the RM-ALONE Trial1 evaluating the safety and workflow efficiency of remote cardiac monitoring with remote interrogations were recently published in the European Heart Journal. The authors analyzed the efficacy of BIOTRONIK Home Mo...
Read more
12
February
2019
| 00:00 Europe/Amsterdam
Data from the BIOLUX P-III All-Comers Registry presented at LINC 2019 highlighted the safety and efficacy of BIOTRONIK’s Passeo-18 Lux* drug-coated balloon (DCB), even in challenging patient subgroups. A number of presentations during LINC congress f...
Read more
2018
17
December
2018
| 00:00 Europe/Amsterdam
BIOTRONIK has announced first enrollment in a multicenter study that aims to demonstrate that a two-lead cardiac resynchronization therapy (CRT) system with atrial sensing is at least as effective as a conventional three-lead system. BIOTRONIK’s CRT-...
Read more
Tags
PR
CRM
CRT